Geographic atrophy is an advanced form of age-related macular degeneration that leads to progressive and permanent loss of central vision.
The disease is driven by the gradual breakdown of retinal pigment epithelium (RPE) cells—critical support cells that maintain the health of photoreceptors, the cells responsible for vision. As these cells deteriorate, patients experience blurred or missing patches in their central vision, impacting everyday activities such as reading, driving, and recognizing faces.
While recent therapies have made progress in slowing disease progression, they do not restore lost vision or address the underlying cause of cell dysfunction.
Our Science
Vision BioSciences is advancing a new class of regenerative therapies for the treatment of vision loss and blindness. We are developing gene therapies designed to restore the health and function of retinal cells, with the goal of improving patient outcomes and enabling durable, long-term protection of vision.
Our platform combines targeted AAV delivery with a focus on retinal pigment epithelium (RPE) cells— reversing cell damage and conferring durable resistance to disease recurrence by using an engineered virus to deliver precise biological signals directly to retinal cells. These signals are designed to help damaged RPE cells recover their function, resist ongoing stress, and better support photoreceptors.
By addressing the underlying health of retinal cells, our approach aims to restore critical visual function and change the trajectory of disease—shifting the paradigm from managing symptoms to targeting the root causes of vision loss.